2月17日，是移植物抗宿主病日（GVHD ...

The addition of itacitinib to standard graft-versus-host-disease prophylaxis may reduce severe toxicities following ...

中国青年报客户端讯（中青报·中青网记者 夏瑾）每年2月17日是移植物抗宿主病日（GVHD ...

2024年12月，美国食品药物管理局（FDA）批准了Mesoblast公司的Ryoncil (remestemcell-l-rkind) ——一种同种异体骨髓间充质基质细胞（MSC）疗法，用于治疗儿科急性类固醇难治性移植物抗宿主病（GVHD），这一获批最终结束了美国长期以来没有MSC药品上市的局面。此前，包括欧洲、日本、印度和韩国在内的多个国家已经批准了自体或同种异体MSC产品。

For over a thousand people who undergo a stem cell or bone marrow transplant, survival comes at a cost: graft-versus-host disease (GvHD). 1 GvHD is a life-altering condition which affects 30 to 40 per ...

“Poor nutrition and poor body weight, as well as a loss of muscle mass, can increase the risk of developing GVHD,” says Michelle Bratton, RD, former nutrition educator with the LLS’s ...

FDA 已批准 remestemcel-L (Ryoncil) 用于治疗类固醇难治性急性移植物抗宿主病 (SR-aGVHD) 的儿科患者。 美国食品药品监督管理局（FDA）批准了 remestemcel-L-rknd ...

There are few prospective studies evaluating the role of extracorporeal photopheresis (ECP) in chronic GVHD (cGVHD) and only occasional reports of the effect of ECP on patients’ quality of life ...

Fred Hutch’s Phase 2 study among blood cancer patients is a “gamechanger” in preventing graft-versus-host disease after ...

Shernan Holtan, MD, has been named the recipient of 2025 Lukas D. Wartman Award. Holtan, chief of blood and marrow ...

Hany Elmariah, MD, discussed the safety profile of fedratinib and its evolving role in the post-transplant setting for patients with myeloproliferative neoplasms.